Products for Research Use Only
RegisterLogin

CDK4/6-IN-2

CAT: 0804-HY-114339-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-114339-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor extracted from patent US20180000819A1, Compound 1, has IC50s of 2.7 and 16 nM for CDK4 and CDK6, respectively[1].
CAS Number
1800506-48-2
UNSPSC
12352005
Hazard Statement
H302-H315-H319
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Neuroscience-Neuromodulation
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cdk4-6-in-2.html
Purity
99.67
Solubility
DMSO : 5.2 mg/mL (ultrasonic)
Smiles
CCN1CCN(CC2=CN=C(NC3=NC=C(F)C(C4=CC(N(C(C)C)C(C)=N5)=C5C(F)=C4)=C3)N=C2)CC1
Molecular Formula
C27H32F2N8
Molecular Weight
506.59
Precautions
P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501
References & Citations
[1]Frank Wu, et al. Kinase inhibitor and use thereof. US20180000819A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK4; CDK6

Chemical Information

Cdk4/6-IN-2

Bireociclib is an orally bioavailable selective inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration, bireociclib selectively targets and inhibits the activity of CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.

CAS Number1800506-48-2
PubChem CID91820696
IUPAC Name5-[(4-ethylpiperazin-1-yl)methyl]-N-[5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)-2-pyridinyl]pyrimidin-2-amine
Molecular FormulaC27H32F2N8
Molecular Weight506.6
XLogP3.8
Topological Polar Surface Area75
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count9
Rotatable Bond Count7
Heavy Atom Count37
Formal Charge0
Complexity715
SMILES
CCN1CCN(CC1)CC2=CN=C(N=C2)NC3=NC=C(C(=C3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F
InChI
InChI=1S/C27H32F2N8/c1-5-35-6-8-36(9-7-35)16-19-13-31-27(32-14-19)34-25-12-21(23(29)15-30-25)20-10-22(28)26-24(11-20)37(17(2)3)18(4)33-26/h10-15,17H,5-9,16H2,1-4H3,(H,30,31,32,34)
InChIKey
CMOYPFUEZDEQEH-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of Cdk4/6-IN-2
CAS: 1800506-48-2
CID: 91820696
Formula: C27H32F2N8
MW: 506.6
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight506.6
XLogP33.8
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count9
Rotatable Bond Count7
Exact Mass506.27179938
Monoisotopic Mass506.27179938
Topological Polar Surface Area75 Ų
Heavy Atom Count37
Formal Charge0
Complexity715
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Related Products

CatalogName
HY-174088CDK4/6/BRD4-IN-2
HY-168444CDK4/6-IN-23
HY-162529CDK4/6-IN-19
HY-143258CDK4/6-IN-8
HY-179151CDK4/6-IN-26
HY-172146CDK4/6-IN-24
HY-115992-01CDK4/6-IN-9
HY-143257CDK4/6-IN-7
HY-142076-01CDK4/6-IN-15
HY-153088-01CDK4/6-IN-16

Alternative Products

CatalogName
MBS5752888CDK4/6-IN-2
A18657-25CDK4/6-IN-2 25mg
A18657-10CDK4/6-IN-2 10mg
A18657-5CDK4/6-IN-2 5mg
A18657-1CDK4/6-IN-2 1mg
A18657-100CDK4/6-IN-2 100mg
A18657-50CDK4/6-IN-2 50mg
MBS5785595CDK4/6-IN-6
T204550-01CDK4/6-IN-23
T72928-01CDK4/6-IN-15

Popular Products